257 related articles for article (PubMed ID: 29844039)
1. Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.
Okoduwa A; Ahmed N; Guo Y; Scipione MR; Papadopoulos J; Eiras DP; Dubrovskaya Y
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844039
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
[TBL] [Abstract][Full Text] [Related]
5. Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections.
Durante-Mangoni E; Andini R; Signoriello S; Cavezza G; Murino P; Buono S; De Cristofaro M; Taglialatela C; Bassetti M; Malacarne P; Petrosillo N; Corcione A; Viscoli C; Utili R; Gallo C
Clin Microbiol Infect; 2016 Dec; 22(12):984-989. PubMed ID: 27545697
[TBL] [Abstract][Full Text] [Related]
6. Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery.
Gomes EC; Falci DR; Bergo P; Zavascki AP; Rigatto MH
Int J Antimicrob Agents; 2018 Jul; 52(1):86-89. PubMed ID: 29501603
[TBL] [Abstract][Full Text] [Related]
7. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.
Urban C; Mariano N; Rahal JJ
Antimicrob Agents Chemother; 2010 Jun; 54(6):2732-4. PubMed ID: 20368401
[TBL] [Abstract][Full Text] [Related]
8. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.
Abdelraouf K; Braggs KH; Yin T; Truong LD; Hu M; Tam VH
Antimicrob Agents Chemother; 2012 Sep; 56(9):4625-9. PubMed ID: 22687519
[TBL] [Abstract][Full Text] [Related]
9. Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.
John JF; Falci DR; Rigatto MH; Oliveira RD; Kremer TG; Zavascki AP
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038262
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
11. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
Roger C; Wallis SC; Louart B; Lefrant JY; Lipman J; Muller L; Roberts JA
J Antimicrob Chemother; 2016 Jun; 71(6):1643-50. PubMed ID: 26957490
[TBL] [Abstract][Full Text] [Related]
12. Risk of Nephrotoxicity Associated With Nonrenally Adjusted Intravenous Polymyxin B Compared to Traditional Dosing.
Maniara BP; Healy LE; Doan TL
J Pharm Pract; 2020 Jun; 33(3):287-292. PubMed ID: 30253682
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.
Rigatto MH; Behle TF; Falci DR; Freitas T; Lopes NT; Nunes M; Costa LW; Zavascki AP
J Antimicrob Chemother; 2015 May; 70(5):1552-7. PubMed ID: 25604744
[TBL] [Abstract][Full Text] [Related]
14. Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections.
Rigatto MH; Vieira FJ; Antochevis LC; Behle TF; Lopes NT; Zavascki AP
Antimicrob Agents Chemother; 2015 Oct; 59(10):6575-80. PubMed ID: 26259799
[TBL] [Abstract][Full Text] [Related]
15. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria.
Ouderkirk JP; Nord JA; Turett GS; Kislak JW
Antimicrob Agents Chemother; 2003 Aug; 47(8):2659-62. PubMed ID: 12878536
[TBL] [Abstract][Full Text] [Related]
16. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy.
Kubin CJ; Ellman TM; Phadke V; Haynes LJ; Calfee DP; Yin MT
J Infect; 2012 Jul; 65(1):80-7. PubMed ID: 22326553
[TBL] [Abstract][Full Text] [Related]
17. Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis.
Vardakas KZ; Voulgaris GL; Samonis G; Falagas ME
Int J Antimicrob Agents; 2018 Jan; 51(1):1-9. PubMed ID: 28669836
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Acute Kidney Injury in Intermittent Versus Continuous Infusion of Polymyxin B in Hospitalized Patients.
Alvarado Reyes Y; Cruz R; Gonzalez J; Perez Y; Wolowich WR
Ann Pharmacother; 2019 Sep; 53(9):886-893. PubMed ID: 30971094
[No Abstract] [Full Text] [Related]
19. Isolation of seven distinct carbapenemase-producing Gram-negative organisms from a single patient.
Creighton J; Heffernan H; Howard J
J Antimicrob Chemother; 2017 Jan; 72(1):317-319. PubMed ID: 27621176
[No Abstract] [Full Text] [Related]
20. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.
Mousavi M; Zapolskaya T; Scipione MR; Louie E; Papadopoulos J; Dubrovskaya Y
Pharmacotherapy; 2017 Mar; 37(3):379-385. PubMed ID: 28079263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
